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Abstract
Objective: Nonsteroidal anti-inflammatory drugs (NSAIDs) increase blood pressure and
potentially cardiovascular burden, which may limit their use in ankylosing spondylitis (AS). Our
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objective was to determine the association of NSAID use with incident hypertension in a
longitudinal AS cohort.
Methods: Adults with AS were enrolled in a prospective cohort study of patient outcomes and
examined every 4–6 months. Hypertension was defined by patient-reported hypertension; anti-
hypertensive medication use; or, on two consecutive visits, systolic blood pressure ≥140 mm Hg
or diastolic ≥90 mm Hg. Continuous NSAID use was dichotomized based on the validated NSAID
index. We assessed the association of NSAID use as a time-varying exposure with the incidence of
hypertension using Cox proportional hazards models.
Results: Of the 1282 patients in the cohort, 628 patients without baseline hypertension had at
least one year of follow up, and were included in the analysis. Of these, 72% were male, the mean
age at baseline was 39 ± 13 years, and 200 used NSAIDs continuously. On follow-up, 129
developed incident hypertension. After controlling for other variables, continuous NSAID use was
associated with a hazard ratio (HR) of 1.12 for incident hypertension (95% CI, 1.04–1.20),
compared to non-continuous or no use. The association did not differ in subgroups defined by age,
body mass index, biologic use, or disease activity.
Conclusion: In our prospective, longitudinal AS cohort, continuous NSAID use was associated
with a 12% increased risk for the development of incident hypertension, as compared to non-
continuous or no NSAID use.
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in many parts of the developed
world, and the evidence for increased CVD burden and cardiovascular (CV) risk in patients
with inflammatory rheumatic diseases is well recognized[1–3]. Multiple population-based
studies have demonstrated increased CV events and CV-related mortality in Ankylosing
Spondylitis (AS)[4–7]. There is a high prevalence of CV risk factors among individuals with
AS, particularly hypertension[8–10].
Currently available guidelines recommend nonsteroidal anti-inflammatory drugs (NSAIDs)
as first-line pharmacological management of AS[11]. However, from meta-analyses of
clinical trials NSAIDs are known to increase blood pressure in both normotensive and
hypertensive individuals[12]. Furthermore, there is an increased relative risk of CV events
with selective cyclooxygenase-2 (COX-2) inhibitors and more mixed data with non-
selective NSAIDs in the general population[13–15]. The potential for both CV risk factors
and CV outcomes may limit this therapy in AS, a population already at high CVD risk.
Conversely, population-level data suggest that NSAID use in AS may be cardioprotective,
possibly via their modulation of the chronic inflammatory state[7,16–19]. Better control of
AS disease activity, in turn, may lead to increases in physical activity and improvements in
CV risk parameters[20]. The effect of NSAID use on CV risk factors such as hypertension
among individuals with AS remains unclear. The purpose of our study was to investigate the
association of NSAID use with the development of incident hypertension in a large
prospective observational cohort of AS patients.
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MATERIALS AND METHODS
Study population
We utilized longitudinal data from the Prospective Study of Outcomes in AS (PSOAS)
cohort. Individuals were recruited from the investigators’ clinics, patient support groups, and
community rheumatologists and were enrolled if they were at least 18 years old and met the
modified New York criteria for AS[21]. There were five participating study sites: Cedars-
Sinai Medical Center (Los Angeles, CA), University of Texas Health Science Center
(Houston, TX), National Institutes of Health (Bethesda, MD), University of California San
Francisco (San Francisco, CA), and Princess Alexandra Hospital, Queensland University of
Technology (Brisbane, Australia). Enrollment for the PSOAS cohort began in 2002 and
continued through 2018.
Data collection
Clinical evaluation was performed using a standardized protocol at study entry and every
four to six months by a study site investigator. At baseline, patient demographics and
characteristics of AS disease status, including HLA-B27 status, date of symptom onset,
patient-reported outcomes, extra-articular manifestations, comorbidities and medication
history were recorded. Comorbid conditions including self-reported hypertension were then
ascertained every two years; these additionally included coronary artery disease, valvular
heart disease, history of heart attack, coronary revascularization, coronary bypass surgery,
diabetes, renal disorders, mental health disorders, in addition to extra-articular
manifestations.
Follow-up evaluations performed every four to six months utilized questionnaires assessing
disease activity and functional impairment [Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI), respectively]
[22]. All medications used in the preceding six months were recorded, per patient report. For
NSAIDs and TNF inhibitors (TNFi), this included the dosage, frequency, and duration. The
number of missed doses in the past week, month, and six months was also documented,
along with whether the patient was still taking the medication. C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR) levels were determined at each study visit. Starting in
2013, vital signs, including blood pressure and body mass index (BMI) measures, were also
recorded at each study visit.
All study data were also entered into REDCap and quality assurance of data for our study
was performed by the Data Management and Statistical Core (DMSC), housed in the
Biostatistics/Epidemiology/Research Design component of the Center for Clinical and
Translational Sciences at the McGovern Medical School at The University of Texas Health
Science Center in Houston. Each institution at which the study was conducted had review
and approval by each of their respective institutional review boards (IRB): Cedars-Sinai,
CR00011435/Pro00010016; University of Texas – Houston, UTH-HSC-MS-07–0022;
University of California – San Francisco, 1–01695, Ref #183280; National Institutes of
Health, #03-AR-0131; Queensland University of Technology, HREC/05/QPAH/221. The
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Human Subjects Division of the University of Washington determined that IRB review was
not necessary for this study.
Variables
Exposure: NSAID usage was quantified by the NSAID index according to Assessment of
SpondyloArthritis international Society (ASAS) recommendations [23]. An individual
taking the full recommended dosage of a particular NSAID in the six months preceding the
study visit would receive an NSAID index of 100, while an individual reporting no use
would receive an index of 0. We used an NSAID index of 50 as the threshold between high
and low NSAID usage, and examined NSAID usage as a binary variable (high versus low or
no use). As there was 90% concordance between high NSAID use and continuous NSAID
use (defined as 50% of the maximum recommended dose, taken daily[24,25]) in our dataset,
we used these terms interchangeably.
Outcome: The standard definition of hypertension, per National Heart Lung and Blood
Institute (NHLBI)-supported cohort studies, is a systolic blood pressure (SBP) of ≥140 mm
Hg, a diastolic blood pressure (DBP) of ≥90 mm Hg, or the use of antihypertensive
medication by a patient who reports a physician diagnosis of hypertension[26]. As study
visits prior to 2013 did not include recorded blood pressures, we used a modified definition
of hypertension. In our study, we defined hypertension as either a patient-reported diagnosis
of hypertension, the use of antihypertensive medication(s), SBP ≥140 mm Hg on two
consecutive study visits, or DBP ≥90 mm Hg on two consecutive study visits. During the
period of cohort follow-up, changes were made in the diagnostic criteria for hypertension in
the United States; our blood pressure criteria reflect the Joint National Committee (JNC8)
guidelines published in 2014[27]. A patient was considered to have a new diagnosis of
hypertension if they did not meet our criteria at the baseline visit, but met criteria at a
subsequent visit.
Other variables: TNFi use was a binary variable indicating use in the six months prior to
the study visit. We calculated the ASDAS as a measurement of disease activity, per recent
recommendations[28]. The score was determined from BASDAI questions 2, 3, and 6, a
patient global score, and the CRP. If the CRP was undectectable or less than 2mg/L, a
constant value of 2mg/L was entered into the calculation[29]. CVD was the composite of
patient-reported histories of any one of the following: coronary artery disease, coronary
bypass surgery, coronary revascularization, heart attack, and angina.
Statistical analysis
We included all study visits for patients who were followed longitudinally in the 2003–2018
study cycles. Due to limited data collected in 2002, we excluded study visits from that year.
We initially included 834 patients in our study cohort.
Those patients with prevalent hypertension at baseline (n=204, 24 % of the cohort), and
those with completely missing NSAID index data (n=2) were then excluded from the
analysis. We performed descriptive statistics of baseline demographic and clinical
characteristics of patients without hypertension at baseline (n=628). Comparisons between
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those on continuous versus non-continuous or no NSAID use at baseline were conducted
using t-tests with unequal variances for continuous variables or χ2 tests for categorical
variables.
We used multiple imputation with chained equations (MICE) with five iterations to impute
missing values for NSAID use, TNFi use, disease activity, and BMI[30–32]. The other
variables in our full model, including the outcome of interest, were included in the MICE
procedure[33].
To assess the risk of a new diagnosis of hypertension during follow-up, we used Cox
proportional hazards models with NSAID use, TNFi use, and ASDAS modeled as time-
varying-covariates. Potential effect modifiers and confounders were determined a priori. To
assess for interaction of NSAID use with age, BMI, TNFi, and ASDAS on the risk of
incident hypertension, we used a model in which we adjusted for study site, age at study
entry, sex, and race. If variables were not statistically significant at an alpha level of 0.05,
they were included in the fully adjusted, full model as confounders.
Sensitivity analyses:
In a series of sensitivity analyses, we examined the stability of our main model with
alternate definitions of the cohort, the exposure, and the outcome. (1) We restricted our
analysis to those without diabetes, kidney disease, inflammatory bowel disease, and other
CVD, as these conditions are common contraindications to NSAID use (n=569). (2) We
performed a complete case analysis in which we adjusted for study site, age at study entry,
sex, race, TNFi use, and ASDAS. We did not include BMI in this model as this would limit
our observations to the last five years of visits, reducing the precision of our estimates. (3)
We defined the outcome of incident hypertension by using only a patient report of using
anti-hypertensive medication. As this also affected the definition of baseline hypertension,
we had 701 patients without baseline hypertension available in this analysis. (4) We defined
the outcome of incident hypertension by using either a patient report of anti-hypertensive
medication use or a diagnosis of hypertension. (5) To ensure that high and continuous
NSAID use were interchangeable, we defined continuous NSAID use based on daily use of
50% of the maximum dose of each medication, as captured in the month prior to each study
visit, rather than using the calculated NSAID index (over the prior 6 month period). For
visits with calculated NSAID indices that did not have available NSAID use information
from the preceding month, non-continuous NSAID use was imputed.
A significance level of 0.05 and robust standard error estimates were used for all models.
Analyses were conducted in STATA (version 15, StataCorp, College Station, Texas).
RESULTS
There were 834 individuals with AS from the PSOAS cohort with at least one year of follow
up. After excluding those with missing NSAID index data (n=2) and those with baseline
hypertension (n=204), 628 individuals remained. Baseline characteristics of the cohort
entered into the main analysis, stratified by first available NSAID use, are shown in Table 1.
Overall, the mean age at study entry was 39±13 years, 72% were male, and 80% were white.
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The mean symptom duration at study entry was 16±12 years, and individuals had a mean
ASDAS 2.0±0.9. The mean weekly exercise duration was 164±208 minutes. Forty-three
percent were on biologic medications, the majority of which were TNFi, and 7% were on
glucocorticoids. Two percent had any CVD, 1% had diabetes, and 3% reported taking a
statin medication.
Of these 628 individuals in the analysis, 200 reported continuous NSAID use by the NSAID
index and 428 reported low dose or no NSAID use. Demographic characteristics between
the two groups were similar, but those taking continuous NSAIDs at baseline had
significantly higher disease activity by both the BASDAI (p=0.03) and ASDAS (p=0.04),
and a greater proportion had an elevated CRP (p=0.03). There were more patients on
biologics in the non-continuous or no NSAID use group than in the continuous NSAID use
group (47% vs. 33%, p<0.001).
During a median (interquartile range) of 7.0 (5.2) years of follow up, a new diagnosis of
hypertension occurred in 129 patients. Of these patients who had incident hypertension on
follow-up, at baseline 52 (40%) were on continuous NSAIDs, 60 (47%) were on TNFi, and
21 (16%) were on both continuous NSAID and TNFi. Kaplan-Meier curves stratified by
NSAID use are shown in the Figure. After adjustment for study site, age, sex, race, BMI,
TNFi use, and disease activity by ASDAS, continuous NSAID use was associated with an
increased risk of incident hypertension, compared with non-continuous or no NSAID use
(HR 1.12, 95%CI 1.04–1.20) (Table 2). In this model, other significant predictors of incident
hypertension included baseline age (HR 1.07 per year, 95%CI 1.06–1.09) and obese BMI
(HR 3.24, 95% CI 1.86–5.63). The association did not differ in subgroups defined by age
(p=0.93), BMI (p=0.60), disease activity (p=0.23), or TNFi use (p=0.89).
We obtained similar results across the sensitivity analyses (Supplemental Table). In all
models continuous NSAID use and greater age at study entry remained significant predictors
of incident hypertension, after adjustment for other variables in the model. However, TNFi
use and disease activity were statistically significant predictors of incident hypertension in
the complete case analysis (HR 1.08, 95% CI 1.01–1.17 for TNFi use; HR 1.09, 95% CI
1.04–1.14 for disease activity) and the model in which the outcome was defined by anti-
hypertensive medication use only (HR 1.08, 95% CI 1.00–1.17 for TNFi use; HR 1.07, 95%
CI 1.02–1.12 for disease activity).
DISCUSSION
In our prospective, longitudinal AS cohort, continuous NSAID use, after adjustment for
demographic and clinical characteristics, was associated with an approximately 12%
increased risk for the development of incident hypertension on follow-up, as compared to
non-continuous or no NSAID use. Our findings support the hypothesis that NSAID use has
negative effects on an important CV risk factor in a population that is known to be at-risk for
CVD.
Individuals with AS may have increased CV mortality, CV events, and risk factors
compared to the general population[5,34]. In a recent systematic review and meta-analysis,
the overall incidence of myocardial infarction (MI) and stroke in AS was 2.6% and 1.9%
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respectively[4]. In a population-based cohort study, the age-adjusted incidence rates of MI
and stroke among individuals with AS aged 50–59 years were 4.4 per 1000 person-years
(95% CI 2.6–6.2) and 3.0 per 1000 person-years (95% CI 1.5–4.4), respectively[6].
Traditional CV risk factors, including diabetes mellitus, hypertension, dyslipidemia, and
obesity are prevalent in AS; the prevalence of hypertension ranges from 11–44%[8–10,35].
NSAIDs are the first-line pharmacological therapy in AS, but they are also known to
increase blood pressure in normotensive and hypertensive individuals in the general
population[12]. In the broader peripheral and axial spondyloarthritis (SpA) population,
factors associated with prevalent hypertension have only been examined cross-
sectionally[36]. In this study, there was a significant association of hypertension with
disease duration, but not with self-reported NSAID use compared with no use. The
interpretation of these results are limited by the study design and unmeasured residual
confounding.
In our study, there was an association between NSAID use and the development of
hypertension in AS. This is likely due to the strength of our longitudinal study with available
medication use data. We also have a more homogenous cohort of individuals with AS, who
tend to have more severe disease than a more broadly defined axial SpA population. The
stability of our estimates across multiple models lends further support for our findings.
We did not find evidence for interactions between TNFi use and NSAID use, or disease
activity and NSAID use, on incident hypertension. Interestingly, TNFi use was significantly
associated with incident hypertension after adjustment for potential confounders in two of
the sensitivity analyses. Although TNFi use did not reach statistical significance in the main
model, the direction of association was opposite that hypothesized based on prior data,
specifically that TNFi use reduces CV risk by suppressing chronic inflammation. Prior
studies of TNFi use on subclinical atherosclerosis in AS have suggested that CVD risk is
reduced alongside the reduction of inflammation[37–41]. However, similar studies in AS did
not demonstrate signifcant changes in blood pressure with TNFi use, likely due to their
small sample size and short duration of follow-up[42,43]. Studies of the association between
TNFi use and development of HTN have been mixed in RA. A meta-analysis of randomized
controlled trials suggested that TNFi use was associated with an increased risk of developing
HTN[44], although this was not replicated in a subsequent study[45]. Whether the findings
in RA translate to AS is unclear. The association of TNFi use and incident hypertension
requires further clarification in future studies, which may be done by applying a marginal
structural modeling (MSM) framework and inverse probability of treatment weighting
(IPTW) statistical analyses to account for the relationships between TNFi use, disease
activity, and NSAID use.
The association of NSAIDs and incident HTN remains particularly concerning, as the early
development of HTN may portend a higher risk of premature CV events due to cumulative
exposure[46,47]. The anti-inflammatory effects of NSAIDs are mediated through COX-2
inhibition and vasoconstriction. NSAID use is associated with downstream effects on CV
events in the general population[13–15,48,49]; these effects may be different in individuals
with AS or SpA. Dubreuil, et al. performed a nested case-control study using a UK primary
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care database, in which they evaluated NSAID exposure on the outcome of MI in SpA and
osteoarthritis (OA) cohorts[19]. In both cohorts, current diclofenac use compared with
remote use was associated with increased MI risk (for SpA, adjusted OR 3.32, 95%CI 1.57,
7.03; for OA, adjusted OR 1.26, 95% CI 1.14,1.39), whereas current naproxen use compared
with remote use was not (for SpA, adjusted OR 1.19, 95% CI 0.53, 2.68; for OA, adjusted
OR 0.98, 95% CI 0.85,1.13). The risk differed between the two types of arthritis (ratio of
ratios 2.64, 95% CI 1.24, 5.58). Using the Taiwan National Health Insurance Database, Tsai,
et al. found that frequent NSAID users (medication possession rate (MPR) ≥80%) had a
significantly lower odds of a combined major CV event endpoint at 12 months, compared
with non-frequent NSAID users (MPR<80%) (OR 0.23, 95% CI 0.07, 0.76)[16]. In a
Taiwanese case-control study of AS patients, celecoxib use was found to have a negative
association with CV events, compared with non-use (OR 0.34, 95% CI 0.13, 0.89)[17].
Patients with AS unexposed to NSAIDs had more baseline comorbidities and an increased
risk of congestive heart failure in a Swedish registry study, although these findings may be
limited by confounding by indication, as those with CV risk factors have contraindications
to NSAIDs[18]. Finally, as a secondary outcome in a study using the Ontario administrative
database, Haroon, et al found that lack of NSAID exposure in those 65 and older was
associated with increased risk of vascular death[7].
Our study was strengthened by the use of a large, prospective cohort with a lengthy duration
of follow-up, as well as the inclusion of detailed dosage and frequency data on the NSAID
use. Our study had limitations. Our ability to make causal inference is limited by the use of
observational data. We considered confounding by indication as patients were not
randomized to NSAID therapy. Baseline comorbidities that would lead to a contraindication
for NSAID use were similar between NSAID use groups. Nevertheless, residual
confounding by extraarticular manifestations and cumulative disease activity over time
likely remains. We also performed a restricted analysis in patients without typical NSAID
contraindications, further supporting our findings overall. We used a definition of
hypertension that was dependent in part on a patient-reported diagnosis of hypertension and
anti-hypertensive medication use, which may lead to nondifferential misclassification of the
outcome. Development and diagnosis of hypertension may have occurred in between study
visits. We had missing data, which we addressed using multiple imputation under the
assumption that data are missing at random, which may not be true. Although the complete
case analysis does not directly mitigate bias from the use of multiple imputation, the
similarity of results to the main model lend further support to the robustness of the primary
finding. Finally, the prospective cohort study design limits our ability to evaluate the
association between NSAID use and CV events such as MI or stroke, as they are rare
outcomes.
In our prospective, longitudinal cohort of individuals with AS, we found that continuous
NSAID use was associated with an increased risk of incident hypertension on follow-up, as
compared to non-continuous or no NSAID use. These data also suggest increased
hypertension risk with TNFi use, although the results were not significant across all models.
This study highlights potential negative CV effects of first-line pharmacological therapy for
AS. Due to the paucity of available data, current guidelines do not specifically address the
prevention or management of CVD in individuals with AS[11,50]. There is an unmet need
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to clarify how treatment choices, particularly the use of NSAIDs and TNFi, impact CV risk
factors and CV events in AS. Further studies are needed to focus on precision medicine and
predicting risk and benefit for patients in whom continuous NSAIDs are being considered.
These further studies can inform the revision of guidelines to address the management of
CV risk factors and CVD in AS and axSpA more broadly.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE AND INNOVATIONS
• Continuous NSAID use, as compared to non-continuous or no NSAID use,
was associated with a modestly increased risk for the development of incident
hypertension in this prospective AS cohort, after controlling for potential
confounders.
• Our findings support the hypothesis that NSAID use has negative effects on
an important cardiovascular risk factor in a population that is known to be at-
risk for cardiovascular disease.
• The associations of TNFi use and disease activity with incident hypertension
require further study and clarification.
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Figure 1.
Kaplan-Meier graph of incident hypertension over follow-up.
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Table 1.
Baseline demographic and clinical characteristics of subjects without hypertension at baseline, stratified by
first available NSAID use.
Variables Whole cohort (n=628)
Continuous NSAID use
(n=200)
Non-continuous or no
NSAID use (n=428) p-valued
Demographics
Age, years 39.4 ± 12.9 38.8 ± 12.5 39.6 ± 13.1 0.69
Male gender 72% 74% 72% 0.41
White race 80% 82% 79% 0.08
Disease characteristics
Age at symptom onset, yearsa 23.9 ± 9.2 23.4 ± 8.0 24.1 ± 9.7 0.59
Symptom duration, yearsa 15.7 ± 11.9 15.6 ± 11.6 15.8 ± 12.1 0.78
BASDAI (0–10)a 3.7 ± 2.4 3.5 ± 2.4 4.1 ± 2.5 0.03
ASDAS (0–10)a 2.0 ± 0.9 1.9 ± 0.9 2.1 ± 0.9 0.04
Exercise, minutes/week 164.2 ± 208.1 163.5 ± 243.0 165.1 ± 77.5 0.94
Abnormal CRPa,b 37% 43% 35% 0.03
Biologic use 43% 33% 47% <0.001
Glucocorticoid use 7% 8% 6% 0.60
Cardiovascular disease and risk factors
Obese BMIa 22% 25% 21% 0.21
Cardiovascular diseasea,c 2% 2% 3% 0.43
Diabetesa 1% 2% 1% 0.26
Current smoker 10% 12% 9% 0.52
Statin use 3% 2% 3% 0.58
a
Data were missing for age at symptom onset (n=61), symptom duration (n=61), BASDAI (n=3), ASDAS (n=7), exercise (n=2), abnormal CRP
(n=3), obese BMI (n=317), cardiovascular disease (n=10), and diabetes (n=9).
b
CRP was abnormal if above the upper limit of the reference range associated with the value.
c
Cardiovascular disease was the composite of patient-reported coronary artery disease, coronary bypass surgery, coronary angioplasty, heart attack,
heart valve problems, and angina.
d
p-value refers to the difference between NSAID use strata as assessed by t-test for continuous variables or χ2 test for categorical variables.
Abbreviations: NSAID: Nonsteroidal anti-inflammatory drug; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BMI: body mass index
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Table 2.
Association of patient characteristics with incident hypertension in a multivariable model (n=628).
Variables HR 95% CI p-value
Age at study entry, per year 1.07 1.06–1.09 <0.01
Male gender 0.94 0.61–1.45 0.79
White race, versus non-white 1.28 0.71–2.30 0.42
Obese BMI 3.24 1.86–5.63 <0.01
Continuous NSAID use, versus non-continuous or no usea 1.12 1.04–1.20 <0.01
ASDAS, per pointa 1.04 0.99–1.09 0.06
TNFi usea 1.07 0.99–1.16 0.09
Model also adjusted for study site.
a
Time-varying covariates
Abbreviations: BMI: body mass index; NSAID: nonsteroidal anti-inflammatory drug; ASDAS: Ankylosing Spondylitis Disease Activity Score;
TNFi: tumor necrosis factor inhibitor; HR; hazard ratio; CI: confidence interval
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